home / stock / gthx / gthx articles

GTHX Articles, G1 Therapeutics Inc.

Stock Information
Company Name: G1 Therapeutics Inc.
Stock Symbol: GTHX
Market: NASDAQ
Website: g1therapeutics.com
Menu
GTHX GTHX Quote GTHX Short GTHX News GTHX Articles GTHX Message Board
Get GTHX Alerts

News, Short Squeeze, Breakout and More Instantly...
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge | Benzinga

Monday, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) revealed topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi t...

Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? | Benzinga

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) are trading lower after the company released topline results from the final OS analysis of its Phase 3 ...

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) | Benzinga

- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population - -...
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) | Benzinga

- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 AD...

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting | Benzinga

RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today a...

G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit | Benzinga

RESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today a...
What's Going On With G1 Therapeutics Stock? | Benzinga

G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer.  What To Know: Accor...

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024 | Benzinga

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, will ...

G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference | Benzinga

RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today...
Next 10